文献速递慢阻肺

多西环素长期治疗对稳定期慢阻肺急性加重率影响的随机对照试验

A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

这项双盲随机安慰剂对照试验纳入222例中度至极重度且有急性加重史的慢阻肺患者,随机接受多西环素100mg每日一次或安慰剂治疗12个月。结果显示多西环素未显著降低年急性加重率(RR 0.86,95%CI 0.67-1.10,P=0.23),但预设亚组分析提示在重度慢阻肺及血嗜酸性粒细胞<300 cells/μl患者中可能获益。

要点

  • 多西环素100mg每日一次治疗12个月未显著降低总体慢阻肺急性加重率。
  • 重度慢阻肺亚组(RR 0.36)及血嗜酸性粒细胞<300 cells/μl亚组(RR 0.50)可能获益。
  • 多西环素组12个月时圣乔治呼吸问卷评分较安慰剂组差5.2分(P<0.007)。

核心结论

  • 在经常发生急性加重的慢阻肺患者中,多西环素治疗12个月未显著降低急性加重率。
  • 预设亚组分析提示多西环素可能对重度慢阻肺或血嗜酸性粒细胞<300 cells/μl的患者有益。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,从英国三个中心招募中度至极重度慢阻肺且有急性加重史的患者。
  • 共222例患者随机接受多西环素100mg每日一次或安慰剂治疗12个月。
  • 主要结局为每人年急性加重率。

主要发现

  • 基线平均FEV1为1.35 L(SD 0.35 L),占预计值52.5%(SD 15.9%)。
  • 研究前一年治疗急性加重中位数为2次(SD 1-4),71%患者报告至少2次急性加重,81%基线已使用吸入糖皮质激素。
  • 多西环素组与安慰剂组急性加重率无差异(RR 0.86,95%CI 0.67-1.10,P=0.23)。
  • 仅考虑治疗急性加重或住院时亦无差异。
  • 预设亚组分析中,重度慢阻肺患者RR 0.36(95%CI 0.15-0.85,P=0.019),血嗜酸性粒细胞<300 cells/μl患者RR 0.50(95%CI 0.29-0.84,P=0.01)。

关键数值与推荐

  • 多西环素用法为100mg每日一次,疗程12个月。
  • 主要结局急性加重率组间比较RR 0.86(95%CI 0.67-1.10,P=0.23)。
  • 重度慢阻肺亚组RR 0.36(95%CI 0.15-0.85,P=0.019)。
  • 血嗜酸性粒细胞<300 cells/μl亚组RR 0.50(95%CI 0.29-0.84,P=0.01)。
  • 圣乔治呼吸问卷评分多西环素组差5.2分(P<0.007)。

临床怎么用

  • 不推荐对经常急性加重的慢阻肺患者常规使用多西环素长期治疗以预防急性加重。
  • 对重度慢阻肺或血嗜酸性粒细胞<300 cells/μl的患者,多西环素可能作为个体化选择,但需权衡健康状态可能恶化的风险。

局限性

  • 预设亚组分析结果需谨慎解读,可能受多重比较影响。
  • 研究仅纳入有急性加重史的中度至极重度慢阻肺患者,结论外推受限。
  • 81%患者基线已使用吸入糖皮质激素,可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of morbidity and mortality, and preventing them is a key treatment target. Long-term macrolide treatment is effective at reducing exacerbations, but there is a paucity of evidence for other antibiotic classes. Objectives: To assess whether 12-month use of doxycycline reduces the exacerbation rate in people with COPD. Methods: People with moderate to very severe COPD and an exacerbation history were recruited from three UK centers and randomized to 12 months of doxycycline 100 mg once daily or placebo. The primary study outcome was the exacerbation rate per person-year. Results: A total of 222 people were randomized. Baseline mean FEV1 was 1.35 L (SD, 0.35 L), 52.5% predicted (SD, 15.9% predicted). The median number of treated exacerbations in the year before the study was 2 (SD, 1-4). A total of 71% of patients reported two or more exacerbations, and 81% were already prescribed inhaled corticosteroids at baseline. The COPD exacerbation rate did not differ between the groups (doxycycline/placebo rate ratio [RR], 0.86; 95% confidence interval [CI], 0.67-1.10; P = 0.23). No difference was seen if only treated exacerbations or hospitalizations were considered. In preplanned subgroup analysis, doxycycline appeared to better reduce the exacerbation rate among people with severe COPD (RR, 0.36; 95% CI, 0.15-0.85; P = 0.019) and in those with an eosinophil count <300 cells/μl (RR, 0.50; 95% CI, 0.29-0.84; P = 0.01). Health status measured by St. George's Respiratory Questionnaire was 5.2 points worse in the doxycycline group at 12 months (P < 0.007). Conclusions: Doxycycline did not significantly reduce the exacerbation rate, over 12 months, in participants with COPD who exacerbated regularly, but it may have benefitted those with more severe COPD or blood eosinophil counts <300 cells/μl. Clinical trial registered with www.clinicaltrials.gov (NCT02305940).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Allinson, Vlies, Brill, et al. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023. PMID: 37450935. doi:10.1164/rccm.202212-2287OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。